Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Orally Inhaled Aerosolized Hydroxychloroquine Sulfate in Healthy Adult Volunteers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04461353
Recruitment Status : Completed
First Posted : July 8, 2020
Last Update Posted : October 8, 2020
Sponsor:
Collaborator:
Rockefeller University
Information provided by (Responsible Party):
Pulmoquine Therapeutics, Inc

Brief Summary:

This study is 'A Randomized Phase 1 Double Blind Placebo Controlled, Single-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Orally Inhaled Aerosolized Hydroxychloroquine Sulfate in Healthy Adult Volunteers.' The primary objectives are as follows:

  • To assess the safety and tolerability of AHCQ administered as a single dose by oral inhalation in healthy individuals at escalating doses until either the maximum tolerated dose (MTD) is identified or 1 mL of a 50 mg/mL solution is administered.
  • To determine the recommended Phase 2a dose (RP2D).

Secondary objectives:

• To characterize pharmacokinetics (PK) of single dose AHCQ in healthy individuals.


Condition or disease Intervention/treatment Phase
Severe Acute Respiratory Syndrome Coronavirus 2 Drug: Aerolized Hydroxychloroquine Sulfate Other: Placebo Phase 1

Detailed Description:

Study Design:

This is a randomized, double-blind placebo-controlled Phase 1 single-dose dose-escalation study to assess the safety, tolerability and PK of oral inhalation of AHCQ in healthy participants.

Escalating single doses of AHCQ will be studied in healthy participants. The study drug will be administered by inhalation through the mouth, and participants will be encouraged to exhale through the nose. The study drug, AHCQ, will be administered starting at an initial dose of 20 mg (Cohort A1, 1 mL of 20 mg/mL AHCQ solution) with a proposed subsequent doses of 50 mg (Cohort A2, 1 mL of 50 mg/mL AHCQ).

Number of Participants (Planned):

Two dose levels are planned to be evaluated. Each cohort will comprise 8 participants (6 active, 2 placebo). Therefore, 16 participants will initially be planned to be enrolled in the study. Additional participants may be enrolled if one or more enrolled participants do not complete the study.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 12 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description:

This is a randomized, double-blind placebo-controlled Phase 1 single-dose dose-escalation study to assess the safety, tolerability and PK of oral inhalation of AHCQ in healthy participants.

A sentinel dose strategy will be employed and the decision to escalate to the next dose level, or deescalate or stop the study, will be based on review and analysis of all available blinded safety and tolerability data by the Safety Review Committee (SRC), which will make a recommendation to the Sponsor and the Sponsor will inform the PI of the recommendation.

Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 1 Randomized Double Blind Placebo Controlled, Single-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Orally Inhaled Aerosolized Hydroxychloroquine Sulfate in Healthy Adult Volunteers
Actual Study Start Date : June 25, 2020
Actual Primary Completion Date : August 17, 2020
Actual Study Completion Date : August 17, 2020


Arm Intervention/treatment
Active Comparator: Hydroxychloroquine Sulfate
The study drug AHCQ will be administered by inhalation through the mouth. The starting dose will be 20 mg (Cohort A1) with a proposed subsequent dose of 50 mg (Cohort A2). At each dose level 8 participants (including at least 3 female participants and 3 participants older than 50 years old) will be enrolled. Six participants will receive the active study drug and 2 participants will receive placebo.
Drug: Aerolized Hydroxychloroquine Sulfate
sterile AHCQ 100 mg/mL for inhalation, is a clear solution packaged in clear glass vials and stored at room temperature.
Other Name: AHCQ

Placebo Comparator: Placebo
Placebo will be administered by inhalation through the mouth. It will be administered in both Cohort A1 and Cohort A2. Six participants will receive the active study drug and 2 participants will receive placebo.
Other: Placebo
The placebo product and diluent solution is sodium chloride inhalation solution, United States Pharmacopeia (USP) 0.9%.




Primary Outcome Measures :
  1. Incidences of treatment-emergent adverse events (TEAEs) as assessed by TGSHAAV (September 2007) or CTCAE version 5.0 [ Time Frame: after treatment (Day 1) through to Day 30 ]
    TEAEs (defined as AEs with onset after study drug administration or existing AEs that worsen in severity after study drug administration)

  2. Change from baseline in clinical laboratory test results for CBC with differential [ Time Frame: Screening and Day 8 ]
    Blood sample collected for CBC with differential will be assessed from baseline (at screening)

  3. Incidence of abnormal laboratory test results for CBC with differential at Screening [ Time Frame: Screening ]
    Screening blood sample collected for CBC with differential, counting the number of abnormal clinical tests

  4. Incidence of abnormal laboratory test results for CBC with differential - Day 8 [ Time Frame: Day 8 ]
    Day 8 blood sample collected for CBC with differential

  5. Changes from baseline for blood glucose [ Time Frame: Screening and Day 1 ]
    Blood sample collected for blood glucose and measured with a glucometer

  6. Incidence of abnormal laboratory test results for chemistry -Screening [ Time Frame: Screening ]
    Blood sample collected for chemistry panel (albumin, total protein, ALP, ALT, AST, direct and indirect bilirubin, GGT, BUN, creatinine, glucose, bicarbonate, calcium, chloride, magnesium, phosphate, potassium, sodium, and LDH)

  7. Incidence of abnormal laboratory tests results for chemistry - Day 8 [ Time Frame: Day 8 ]
    Blood sample collected for chemistry panel (albumin, total protein, ALP, ALT, AST, direct and indirect bilirubin, GGT, BUN, creatinine, glucose, bicarbonate, calcium, chloride, magnesium, phosphate, potassium, sodium, and LDH)

  8. Incidence of abnormal laboratory tests results for urinalysis - Screening [ Time Frame: Screening ]
    Collection of urine sample to test pH, specific gravity, protein, glucose, ketones, urobilinogen, bilirubin, leukocyte esterase, squamous cells, epithelial cells, clarity, bacteria, blood

  9. Incidence of abnormal laboratory tests results for urinalysis- Day 8 [ Time Frame: Day 8 ]
    Collection of urine sample to test pH, specific gravity, protein, glucose, ketones, urobilinogen, bilirubin, leukocyte esterase, squamous cells, epithelial cells, clarity, bacteria, blood

  10. Changes in vital signs from baseline (pre-dose) - respiratory rate [ Time Frame: Screening, Day 1, Day 2 and Day 8 ]
    The Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventative Vaccine Clinical Trials (September 2007) (TGSHAAV) will be used as the primary criteria for assessment of clinical abnormalities. Mild (17-20 breaths per minute) to Potentially Life Threatening (intubation)

  11. Changes in vital signs from baseline (pre-dose)- temperature [ Time Frame: Screening, Day 1, Day 2 and Day 8 ]
    Oral temperature

  12. Changes in vital signs from baseline (pre-dose) - seated blood pressure [ Time Frame: Screening, Day 1, Day 2 and Day 8 ]
    Systolic and diastolic blood pressure

  13. Changes in vital signs from baseline (pre-dose) - pulse [ Time Frame: Screening, Day 1, Day 2 and Day 8 ]
    Heart rate measure by radial pulse rate (beats/min)

  14. Changes in vital signs from baseline (pre-dose) - O2 saturation [ Time Frame: Screening, Day 1, Day 2 and Day 8 ]
    O2 saturation (%), measured by pulse oximeter. Graded as per TGSHAAV (September 2007) from Moderate (pulse oximeter <92%) to Potentially Life Threatening (Life-threatening airway compromise; urgent intervention indicated)

  15. Incidence of abnormal and physical examinations findings during Screening- general appearance [ Time Frame: Screening ]
    Physical exam by clinician. A directed physical examination will be conducted

  16. Incidence of abnormal and physical examinations findings on Day 1 - general appearance [ Time Frame: Day 1 ]
    Physical exam by clinician. A directed physical examination assessing and documenting changes from the previous visit, including any new abnormalities, will be conducted

  17. Incidence of abnormal and physical examinations findings on Day 2- general appearance [ Time Frame: Day 2 ]
    Physical exam by clinician. A directed physical examination assessing and documenting changes from the previous visit, including any new abnormalities, will be conducted

  18. Incidence of abnormal and physical examinations findings on Day 8- general appearance [ Time Frame: Day 8 ]
    Physical exam by clinician. A directed physical examination assessing and documenting changes from the previous visit, including any new abnormalities, will be conducted

  19. Incidence of abnormal and physical examinations findings during Screening- neurological [ Time Frame: Screening ]
    Physical exam by clinician. A directed physical examination will be conducted

  20. Incidence of abnormal and physical examinations findings on Day 1- neurological [ Time Frame: Day 1 ]
    Physical exam by clinician. A directed physical examination assessing and documenting changes from the previous visit, including any new abnormalities, will be conducted

  21. Incidence of abnormal and physical examinations findings on Day 2- neurological [ Time Frame: Day 2 ]
    Physical exam by clinician. A directed physical examination assessing and documenting changes from the previous visit, including any new abnormalities, will be conducted

  22. Incidence of abnormal and physical examinations findings on Day 8- neurological [ Time Frame: Day 8 ]
    Physical exam by clinician. A directed physical examination assessing and documenting changes from the previous visit, including any new abnormalities, will be conducted

  23. Incidence of abnormal and physical examinations findings during Screening - heart/cardiovascular [ Time Frame: Screening ]
    Physical exam by clinician. A directed physical examination will be conducted

  24. Incidence of abnormal and physical examinations findings on Day 1 - heart/cardiovascular [ Time Frame: Day 1 (pre-dose, within 3 hours of dose) ]
    Physical exam by clinician. A directed physical examination assessing and documenting changes from the previous visit, including any new abnormalities, will be conducted

  25. Incidence of abnormal and physical examinations findings on Day 2 - heart/cardiovascular [ Time Frame: Day 2 ]
    Physical exam by clinician. A directed physical examination assessing and documenting changes from the previous visit, including any new abnormalities, will be conducted

  26. Incidence of abnormal and physical examinations findings on Day 8 - heart/cardiovascular [ Time Frame: Day 8 ]
    Physical exam by clinician. A directed physical examination assessing and documenting changes from the previous visit, including any new abnormalities, will be conducted

  27. Incidence of abnormal and physical examinations findings during Screening - lungs [ Time Frame: Screening ]
    Physical exam by clinician. A directed physical examination will be conducted

  28. Incidence of abnormal and physical examinations findings on Day 1 - lungs [ Time Frame: Day 1 ]
    Physical exam by clinician. A directed physical examination assessing and documenting changes from the previous visit, including any new abnormalities, will be conducted

  29. Incidence of abnormal and physical examinations findings on Day 2 - lungs [ Time Frame: Day 2 ]
    Physical exam by clinician. A directed physical examination assessing and documenting changes from the previous visit, including any new abnormalities, will be conducted

  30. Incidence of abnormal and physical examinations findings on Day 8 - lungs [ Time Frame: Day 8 ]
    Physical exam by clinician. A directed physical examination assessing and documenting changes from the previous visit, including any new abnormalities, will be conducted

  31. Incidence of abnormal and physical examinations findings during Screening- abdomen [ Time Frame: Screening ]
    Physical exam by clinician. A directed physical examination will be conducted

  32. Incidence of abnormal and physical examinations findings on Day 1 - abdomen [ Time Frame: Day 1 ]
    Physical exam by clinician. A directed physical examination assessing and documenting changes from the previous visit, including any new abnormalities, will be conducted

  33. Incidence of abnormal and physical examinations findings on Day 2- abdomen [ Time Frame: Day 2 ]
    Physical exam by clinician. A directed physical examination assessing and documenting changes from the previous visit, including any new abnormalities, will be conducted

  34. Incidence of abnormal and physical examinations findings on Day 8- abdomen [ Time Frame: Day 8 ]
    Physical exam by clinician. A directed physical examination assessing and documenting changes from the previous visit, including any new abnormalities, will be conducted

  35. Incidence of abnormal and physical examinations findings during screening- endocrine [ Time Frame: Screening ]
    Physical exam by clinician. A directed physical examination will be conducted

  36. Incidence of abnormal and physical examinations findings on Day 1 - endocrine [ Time Frame: Day 1 ]
    Physical exam by clinician. A directed physical examination assessing and documenting changes from the previous visit, including any new abnormalities, will be conducted

  37. Incidence of abnormal and physical examinations findings on Day 2- endocrine [ Time Frame: Day 2 ]
    Physical exam by clinician. A directed physical examination assessing and documenting changes from the previous visit, including any new abnormalities, will be conducted

  38. Incidence of abnormal and physical examinations findings on Day 8- endocrine [ Time Frame: Day 8 ]
    Physical exam by clinician. A directed physical examination assessing and documenting changes from the previous visit, including any new abnormalities, will be conducted

  39. Incidence of abnormal and physical examinations findings during Screening- extremities [ Time Frame: Screening ]
    Physical exam by clinician. A directed physical examination will be conducted

  40. Incidence of abnormal and physical examinations findings on Day 1- extremities [ Time Frame: Day 1 ]
    Physical exam by clinician. A directed physical examination assessing and documenting changes from the previous visit, including any new abnormalities, will be conducted

  41. Incidence of abnormal and physical examinations findings on Day 2- extremities [ Time Frame: Day 2 ]
    Physical exam by clinician. A directed physical examination assessing and documenting changes from the previous visit, including any new abnormalities, will be conducted

  42. Incidence of abnormal and physical examinations findings on Day 8- extremities [ Time Frame: Day 8 ]
    Physical exam by clinician. A directed physical examination assessing and documenting changes from the previous visit, including any new abnormalities, will be conducted

  43. Incidence of abnormal and physical examinations findings during Screening- lymphatic [ Time Frame: Screening ]
    Physical exam by clinician. A directed physical examination will be conducted

  44. Incidence of abnormal and physical examinations findings on Day 1- lymphatic [ Time Frame: Day 1 ]
    Physical exam by clinician. A directed physical examination assessing and documenting changes from the previous visit, including any new abnormalities, will be conducted

  45. Incidence of abnormal and physical examinations findings on Day 2 - lymphatic [ Time Frame: Day 2 ]
    Physical exam by clinician. A directed physical examination assessing and documenting changes from the previous visit, including any new abnormalities, will be conducted

  46. Incidence of abnormal and physical examinations findings on Day 8- lymphatic [ Time Frame: Day 8 ]
    Physical exam by clinician. A directed physical examination assessing and documenting changes from the previous visit, including any new abnormalities, will be conducted

  47. Incidence of abnormal and physical examinations findings during screening - skin [ Time Frame: Screening ]
    A directed physical examination will be conducted

  48. Incidence of abnormal and physical examinations findings on Day 1 - skin [ Time Frame: Day 1 ]
    Physical exam by clinician. A directed physical examination assessing and documenting changes from the previous visit, including any new abnormalities, will be conducted

  49. Incidence of abnormal and physical examinations findings on Day 2 - skin [ Time Frame: Day 2 ]
    Physical exam by clinician. A directed physical examination assessing and documenting changes from the previous visit, including any new abnormalities, will be conducted

  50. Incidence of abnormal and physical examinations findings on Day 8 - skin [ Time Frame: Day 8 ]
    Physical exam by clinician. A directed physical examination assessing and documenting changes from the previous visit, including any new abnormalities, will be conducted

  51. Changes from baseline for pulmonary function tests (PFTs) - FEV1 [ Time Frame: Screening, Day 1 at pre-dose (within 25 minutes of dose) and at +15 minutes, +1, +3 and +6 hours after study treatment, and on Day 2 and Day 8. ]
    Pulmonary function testing and recording of FEV1, both actual and percent predicted

  52. Changes from baseline for pulmonary function tests (PFTs) - FVC [ Time Frame: Screening, Day 1 at pre-dose (within 25 minutes of dose) and at +15 minutes, +1, +3 and +6 hours after study treatment, and on Day 2 and Day 8. ]
    Pulmonary function testing and recording of FVC, , both actual and percent predicted

  53. Changes from baseline for pulmonary function tests (PFTs) - FEV1/FVC [ Time Frame: creening, Day 1 at pre-dose (within 25 minutes of dose) and at +15 minutes, +1, +3 and +6 hours after study treatment, and on Day 2 and Day 8. ]
    Pulmonary function testing and recording of FEV1/FVC

  54. Changes from baseline for ECG readings - QT interval [ Time Frame: Screening and on Day 1 pre-dose (within 3 hours of dose) and approximately +2 and +6 hours, and on Days 2 and 8. ]

    The ECG will be performed after the participant is allowed to rest seated for at least 5 minutes, before transferring to the examination bed/table for the ECG. ECG will be performed before PFTs or blood drawing.

    ECG QT Interval (msec) will be the assessment parameter.


  55. Changes from baseline for ECG readings - QTcB Interval [ Time Frame: Screening and on Day 1 pre-dose (within 3 hours of dose) and approximately +2 and +6 hours, and on Days 2 and 8. ]

    The ECG will be performed after the participant is allowed to rest seated for at least 5 minutes, before transferring to the examination bed/table for the ECG. ECG will be performed before PFTs or blood drawing.

    ECG QTcB interval (msec) will be the assessment parameter.


  56. Changes from baseline for ECG readings - QRS duration [ Time Frame: Screening and on Day 1 pre-dose (within 3 hours of dose) and approximately +2 and +6 hours, and on Days 2 and 8. ]

    The ECG will be performed after the participant is allowed to rest seated for at least 5 minutes, before transferring to the examination bed/table for the ECG. ECG will be performed before PFTs or blood drawing.

    ECG QRS duration (msec) will be the assessment parameter.


  57. Changes from baseline for ECG readings - PR interval [ Time Frame: Screening and on Day 1 pre-dose (within 3 hours of dose) and approximately +2 and +6 hours, and on Days 2 and 8. ]

    The ECG will be performed after the participant is allowed to rest seated for at least 5 minutes, before transferring to the examination bed/table for the ECG. ECG will be performed before PFTs or blood drawing.

    ECG PR interval (msec) will be the assessment parameter.


  58. Changes from baseline for ECG readings - heart rate [ Time Frame: Screening and on Day 1 pre-dose (within 3 hours of dose) and approximately +2 and +6 hours, and on Days 2 and 8. ]

    The ECG will be performed after the participant is allowed to rest seated for at least 5 minutes, before transferring to the examination bed/table for the ECG. ECG will be performed before PFTs or blood drawing.

    ECG heart rate (beats/min) will be the assessment parameter.


  59. Incidence of abnormal ECG - Screening [ Time Frame: Screening ]

    The ECG will be performed after the participant is allowed to rest seated for at least 5 minutes, before transferring to the examination bed/table for the ECG. ECG will be performed before PFTs or blood drawing.

    ECG QT Interval will be the assessment parameter.


  60. Incidence of abnormal ECG- Day 1 [ Time Frame: Day 1 pre-dose (within 3 hours of dose) and +2 and +6 hours ]

    The ECG will be performed after the participant is allowed to rest seated for at least 5 minutes, before transferring to the examination bed/table for the ECG. ECG will be performed before PFTs or blood drawing.

    ECG QT Interval will be the assessment parameter.


  61. Incidence of abnormal ECG - Day 2 [ Time Frame: Days 2 ]

    The ECG will be performed after the participant is allowed to rest seated for at least 5 minutes, before transferring to the examination bed/table for the ECG. ECG will be performed before PFTs or blood drawing.

    ECG QT Interval will be the assessment parameter.


  62. Incidence of abnormal ECG - Day 8 [ Time Frame: Days 8. ]

    The ECG will be performed after the participant is allowed to rest seated for at least 5 minutes, before transferring to the examination bed/table for the ECG. ECG will be performed before PFTs or blood drawing.

    ECG QT Interval will be the assessment parameter.



Secondary Outcome Measures :
  1. HCQ concentration in whole blood versus time profiles [ Time Frame: Day 1 pre-dose (time 0) and +2, +3, +5, and +15 minutes after dose, and also +1, +2, +4 and +6 hours post-dose completion. Day 2 (+24±4 hours post dose) and Day 8. ]
    Blood samples for PK analysis will be collected via indwelling catheter or via direct venipuncture.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Willing and able to give written informed consent.
  2. Males or females aged ≥18 years old.
  3. Good general health as determined by no acute illness and no clinically significant abnormal findings on medical history, vital signs, laboratory tests, or physical examination at screening that, in the opinion of the PI, would interfere with study drug administration, jeopardize the safety of the study participant, or impact the validity of the study results; participants with stable chronic illness are allowed at the discretion of the PI.
  4. An interpretable 12-lead ECG with a corrected QT (QTc) interval ≤450 ms, according to Bazett's formula, without evidence of clinically significant abnormal findings.
  5. Normal FEV1/FVC ratio, defined as any value above 0.7 or above the lower 5th percentile of normal AND FEV1 >80% of predicted or above the lower 5th percentile of normal.
  6. Pulse oximetry 02 saturation ≥95% in room air.
  7. Negative test result for COVID-19 within 7 days of Day 1 AND concurrent with local hospital policy:

    • A nasopharyngeal swab tested with the ID NOW COVID-19 assay (Abbot). OR
    • A negative RNA-based test result of an oropharyngeal or nasopharyngeal swab or saliva sample performed according to CLIA/CLEP.
  8. Females of child-bearing potential must be non-pregnant, non-lactating, have a negative urine pregnancy test at screening, and agree to use an acceptable form of birth control for 200 days after the last administration of the study drug. Females are considered of non-childbearing potential if they are postmenopausal (last menstrual period at least 1 year before screening) or have been surgically sterilized (documented hysterectomy, tubal ligation, or bilateral oophorectomy) for at least 6 months at screening.
  9. Willing to comply with protocol-defined procedures and complete all study visits.
  10. Willing to use the Inhalation System and exhale through the nose.
  11. Adequate venous access in the left or right arm to allow collection of required blood samples.
  12. Participant understands and communicates in English.
  13. Serum Potassium level ≥3.5 mEq/L, Serum Magnesium level ≥1.5 mg/dL, and Serum Calcium ≥8.5 mg/dL.

Exclusion Criteria:

  1. Any self-reported symptoms of influenza-like or COVID-19-like illness in the 14 days preceding the study visit: Fever >101.4 °F, sore throat, nasal congestion, post-nasal discharge, shortness of breath, gastrointestinal distress, wheezing, cough, headache, or fatigue.
  2. Any history of diagnosed chronic lung disease, including but not limited to asthma or chronic obstructive lung disease.
  3. Symptoms of seasonal allergies or use of any drugs for seasonal allergies or any inhaled (oral/nasal) drugs in the 2 weeks prior to Day 1. Mild seasonal allergy symptoms that have not altered sleep or activity patterns nor required use of over-the-counter (OTC) or prescription medications are allowed.
  4. Any close contact exposure in the past 28 days to a person who was diagnosed as having COVID-19, with or without laboratory confirmation, during that close contact exposure or in the ensuing 14 days OR a similar encounter with a person who was determined to have suspected COVID-19, defined by that person being ordered to enter isolation for that indication by a medical authority. Close contact is defined as being within approximately 6 feet of a COVID-19 case for a prolonged (>10 minutes) period of time and can occur while caring for, living with, visiting, or sharing a healthcare waiting area or room with a COVID-19 patient OR having direct contact with infectious secretions of a COVID-19 patient (e.g., being coughed on), if such contact occurred while not wearing the recommended personal protective equipment for that type of contact [e.g., gowns, gloves, N95 respirator (or equivalent), eye protection].
  5. Any participant with a history of SARS-CoV-2 infection that was confirmed by testing or diagnosed without testing within 4 weeks preceding Day 1. If infection occurred more than 4 weeks prior, candidates may be enrolled if they meet the rest of the eligibility criteria.
  6. Any participant with a history severe respiratory illness that required hospitalization in the 60 days preceding Day 1 OR any participant with a history severe respiratory illness that required hospitalization in the preceding 120 days without full recovery.
  7. Participation in another clinical study that involved treatment with an investigational product or device within 30 days of screening or during the study.
  8. Participants with a known history of human immunodeficiency virus (HIV) infection.
  9. Known, active hepatitis A, B, or C infection.
  10. History of bronchospasm in response to use of an inhalation device.
  11. Use of any prescription medication (except oral contraceptives) during the 30 days prior to study dosing that may affect drug absorption, metabolism and excretion, prolong the QTc interval, affect drug efficacy, or increase the risk of adverse reactions, unless approved by the Principal Investigator.
  12. Use of any OTC product, herbal product, diet aid, hormone supplement, etc., within 7 days prior to dosing unless approved by the Principal Investigator.
  13. Unwilling or unable to provide written informed consent.
  14. Any known hypersensitivity to quinolines (e.g., hydroxychloroquine, chloroquine, primaquine, quinine) or known history of glucose-6-phosphate dehydrogenase (G6PD) deficiency or any contraindication to oral hydroxychloroquine.
  15. Known retinopathy, fundus disease, or macular disease.
  16. Diagnosis of long QT Syndrome.
  17. Smoking of tobacco or non-tobacco substances, or vaping, within the last 6 months.
  18. Severe obesity (body mass index [BMI] ≥35 kg/m2).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04461353


Locations
Layout table for location information
United States, New York
The Rockefeller University
New York, New York, United States, 10065
Sponsors and Collaborators
Pulmoquine Therapeutics, Inc
Rockefeller University
Investigators
Layout table for investigator information
Principal Investigator: Ohad S Bentur, MD, MHA Rockefeller University
Layout table for additonal information
Responsible Party: Pulmoquine Therapeutics, Inc
ClinicalTrials.gov Identifier: NCT04461353    
Other Study ID Numbers: PUL-01
First Posted: July 8, 2020    Key Record Dates
Last Update Posted: October 8, 2020
Last Verified: August 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: There is no plan to make IPD available to other researchers.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Pulmoquine Therapeutics, Inc:
coronavirus
COVID-19
Hydroxychloroquine Sulfate
Hydroxychloroquine
Additional relevant MeSH terms:
Layout table for MeSH terms
Coronavirus Infections
Severe Acute Respiratory Syndrome
Coronaviridae Infections
Nidovirales Infections
RNA Virus Infections
Virus Diseases
Respiratory Tract Infections
Respiratory Tract Diseases
Hydroxychloroquine
Antimalarials
Antiprotozoal Agents
Antiparasitic Agents
Anti-Infective Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antirheumatic Agents